Alyeska Investment Group L.P. Buys 63,762 Shares of Janux Therapeutics, Inc. $JANX

Key Points

• Alyeska Investment Group L.P. increased its stake in Janux Therapeutics by 18.5% after acquiring an additional 63,762 shares, bringing its total ownership to 408,678 shares valued at $11,034,000.
• Janux Therapeutics reported a quarterly earnings per share (EPS) of ($0.55), missing analyst expectations by $0.07, with a projected EPS of ($1.38) for the current fiscal year.
• Multiple research firms have initiated coverage on Janux Therapeutics, with target prices ranging from $42.00 to $72.00, and the stock currently has an average rating of "Buy".

Alyeska Investment Group L.P. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 18.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 408,678 shares of the company's stock after buying an additional 63,762 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.69% of Janux Therapeutics worth $11,034,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in JANX. Adage Capital Partners GP L.L.C. grew its stake in shares of Janux Therapeutics by 19.4% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company's stock valued at $98,673,000 after acquiring an additional 592,824 shares during the period. First Light Asset Management LLC lifted its holdings in Janux Therapeutics by 110.0% during the first quarter. First Light Asset Management LLC now owns 658,824 shares of the company's stock valued at $17,788,000 after purchasing an additional 345,042 shares in the last quarter. MPM Bioimpact LLC boosted its position in shares of Janux Therapeutics by 146.6% in the first quarter. MPM Bioimpact LLC now owns 567,193 shares of the company's stock worth $15,314,000 after purchasing an additional 337,193 shares during the period. RA Capital Management L.P. increased its stake in shares of Janux Therapeutics by 7.9% in the first quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company's stock worth $302,122,000 after purchasing an additional 824,041 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in shares of Janux Therapeutics by 88.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company's stock valued at $2,048,000 after purchasing an additional 35,511 shares during the period. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX traded down $1.03 during trading hours on Tuesday, reaching $23.78. The stock had a trading volume of 479,054 shares, compared to its average volume of 917,243. The stock has a market capitalization of $1.43 billion, a PE ratio of -13.21 and a beta of 2.84. Janux Therapeutics, Inc. has a 52 week low of $21.97 and a 52 week high of $71.71. The company has a 50 day moving average price of $24.56 and a two-hundred day moving average price of $26.53.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). Equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on JANX shares. Piper Sandler started coverage on Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 price target for the company. Raymond James Financial assumed coverage on Janux Therapeutics in a research report on Friday, July 11th. They set an "outperform" rating and a $65.00 target price for the company. Finally, Guggenheim initiated coverage on Janux Therapeutics in a research note on Wednesday, September 3rd. They set a "buy" rating and a $72.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $85.55.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.